Article By:
The Fly
Monday, August 3, 2020 1:36 PM EDT
August 3's topline data from CymaBay's halted Phase 3 study answered key questions for seladelpar around its effect on itch, a hallmark symptom of primary biliary cholangitis, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note.
In this article: CBAY